-
Super-Enhancer RNA Drives NPC Metastasis via NPM1/c-Myc/NDRG
2026-05-05
This study uncovers how carcinogen-induced super-enhancer RNA (seRNA-NPCm) promotes nasopharyngeal carcinoma (NPC) metastasis by activating the NPM1/c-Myc/NDRG1 regulatory axis. The findings advance understanding of NPC progression and suggest new avenues for biomarker development and targeted intervention.
-
Ultrasound-Activated Nanoparticles for Synergistic Lung Canc
2026-05-04
This study introduces a multifunctional, pH-sensitive nanoparticle (M@DRSZ) that integrates chemotherapy, sonodynamic therapy, and immune modulation for lung cancer treatment. Ultrasound stimulation of these nanoparticles generates peroxynitrite and reactive oxygen species, leading to enhanced tumor apoptosis and immune response, offering a new direction for overcoming limitations of current cancer therapies.
-
Rotigotine Modulates Bladder Function in PD: Mechanistic Ins
2026-05-04
This study elucidates how rotigotine, a non-ergoline dopamine D1/D2-like receptor agonist, modulates lower urinary tract function in a rat model of Parkinson’s disease (PD). By dissecting the drug’s receptor-driven effects on micturition reflexes, the research advances understanding of non-motor PD symptoms and informs the design of translational studies on PD-associated bladder dysfunction.
-
Zolmitriptan for Migraine Research: Protocols, Workflows, an
2026-05-03
Unlock new precision in migraine and cluster headache research with Zolmitriptan, a selective 5-HT1B receptor agonist. This article details robust experimental workflows, troubleshooting strategies, and translational insights to maximize reproducibility and data quality in serotonin receptor pharmacology.
-
Synergistic PI3K–AKT–ERK Blockade to Overcome Gefitinib Resi
2026-05-02
Deng et al. introduce a dual-drug nanoplatform that synergistically inhibits PI3K/AKT and ERK pathways, effectively overcoming gefitinib resistance and metastasis in lung adenocarcinoma models. Their integrative approach leverages rational nanoparticle design and multimodal validation, setting a new direction for clinically translatable therapies targeting drug-resistant tumors.
-
Protease Inhibitor Cocktail (100X): Precision in Protein Int
2026-05-02
Discover how the Protease Inhibitor Cocktail safeguards protein samples from degradation during extraction and analysis. This in-depth review explores its scientific foundation, role in advanced assays, and why it outperforms conventional inhibitors for critical workflows like Western blotting and co-immunoprecipitation.
-
Pravastatin Sodium: Advanced HMG-CoA Reductase Inhibitor Wor
2026-05-01
Pravastatin sodium delivers precise, reproducible cholesterol biosynthesis inhibition across cellular and animal models. This article details protocol optimizations, experimental troubleshooting, and assay selection strategies—empowering translational research with APExBIO’s trusted quality.
-
Phenacetin as a Gold-Standard Probe in Intestinal Organoids
2026-04-30
This thought-leadership article examines the mechanistic and strategic role of Phenacetin (N-(4-ethoxyphenyl)acetamide) in modern pharmacokinetic research, particularly within human pluripotent stem cell-derived intestinal organoid models. Integrating recent advances from the European Journal of Cell Biology and related translational literature, we outline best practices for experimental design, highlight APExBIO’s product advantages, and provide actionable guidance for researchers navigating the next era of in vitro drug absorption and metabolism studies.
-
Taltirelin Protects Dopaminergic Neurons in PD Models
2026-04-30
Zheng et al. (2018) demonstrate that Taltirelin, a long-acting TRH analog, confers neuroprotection in cellular and animal models of Parkinson’s disease (PD) by reducing oxidative stress, apoptosis, and pathological protein cleavage. These findings position Taltirelin as a mechanistically distinct candidate for preclinical neuroprotection research.
-
Bufalin Targets STK33 to Suppress Triple-Negative Breast Can
2026-04-29
This study identifies serine/threonine kinase 33 (STK33) as a direct molecular target of Bufalin, a cardiotonic steroid, in triple-negative breast cancer (TNBC). By elucidating Bufalin's mechanism as a degrader of STK33, the research provides a mechanistic foundation for therapeutic strategies in aggressive TNBC subtypes.
-
Cy7 NHS Ester: Practical Guide for Near-Infrared Protein Lab
2026-04-29
Cy7 NHS ester is a sulfonated, hydrophilic near-infrared dye designed for efficient and gentle labeling of proteins, peptides, and other amino-containing biomolecules. It addresses challenges in high-sensitivity in vivo imaging and protein labeling workflows where water solubility and minimized quenching are required. Use is not recommended for long-term solution storage or applications needing organic solvent-only protocols.
-
MHY1485: mTOR Activator Workflows for Autophagy Assays & Bey
2026-04-28
MHY1485 from APExBIO offers precision control over the mTOR signaling pathway, enabling researchers to dissect autophagy, cell survival, and ovarian follicle development with robust reproducibility. This guide translates advanced findings—like those from recent cancer research—into actionable protocols and troubleshooting strategies for diverse experimental models.
-
A40926: Glycopeptide Antibiotic with Potent Anti-Neisseria A
2026-04-28
The reference study reports the discovery and characterization of A40926, a novel glycopeptide antibiotic from Actinomadura, notable for its potent activity against Gram-positive pathogens and, uniquely, Neisseria gonorrhoeae. This work established A40926 as a key dalbavancin precursor and provided technical foundations for its use in antibacterial research and development.
-
Rotigotine: Applied Protocols for Dopamine D2/D3 Receptor Ag
2026-04-27
Rotigotine is a high-affinity dopamine D2/D3 receptor agonist uniquely positioned for modeling Parkinson's disease (PD) and dissecting dopaminergic signaling pathways. This guide delivers stepwise protocols, advanced applications, and troubleshooting insights for leveraging Rotigotine in experimental neuroscience.
-
Paroxetine Mesylate: Bridging Neurocardiac and Oncology Rese
2026-04-27
Explore Paroxetine Mesylate as a selective serotonin reuptake inhibitor with unique cross-domain utility in neurocardiac biomarker research and oncology. This article delivers an evidence-driven synthesis, distinct from protocol-focused or single-domain cancer studies.